Clinical Evaluation of Etafilcon A With Ketotifen

Visual Acuity Clinical Trial

Official title:

Clinical Evaluation of Etafilcon A With Ketotifen

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03388138
• Other study ID #: CR-5930
• Status: Completed
• Phase: Phase 2
• Start date: December 6, 2017
• Est. completion date: February 9, 2018

Study information

• Verified date: March 2022
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study is a randomized, double-masked, bilateral, controlled, two-arm parallel group, multi-site, 1-Week, 2-visit dispensing study. Subjects between the ages of 18-40 will be randomized into a placebo arm or an investigational K-Lens arm.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 143
• Est. completion date: February 9, 2018
• Est. primary completion date: February 9, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.

2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.

3. Between 18 and 39 (inclusive) years of age at the time of baseline visit.

4. The subject must be a habitual lens wearer for a least 6 days/week and for a minimum of 8 hours per day over the last month.

5. The subject's contact lens correction must be in the range of -1.00 D to -6.00 D (inclusive) in each eye.

6. The subject's refractive cylinder must be 1.00 D or less in each eye.

7. Have a spherocylindrical best corrected visual acuity of 20/30 or better in each eye (Snellen Visual Acuity).

Exclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from

participating in the study:

1. Currently pregnant or lactating.

2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.

3. Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear.

4. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.

5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear, history of strabismus, or current monovision, multi-focal, or toric contact lens correction.

6. Any current use of rewetting drops or ocular medication.

7. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).

8. Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Biomicroscopy Scale.

9. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear.

10. Any known hypersensitivity or allergic reaction to ketotifen.

11. Participation in any eye drop, contact lens or lens care product clinical trial within 14 days prior to study enrollment.

12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).

Related Conditions & MeSH terms

• Visual Acuity

Intervention

Combination Product:
• etafilcon A with ketotifen
Etafilcon A with ketotifen

Device:
• 1-Day ACUVUE
1-Day ACUVUE

Locations

Country	Name	City	State
United States	Vue Optical Boutique	Jacksonville	Florida
United States	Maitland Vision Center	Maitland	Florida
United States	Kannarr Eye Care	Pittsburg	Kansas
United States	Botetourt Eyecare, LLC	Salem	Virginia
United States	St. Lucy's Vision Center	Tampa	Florida
United States	Sacco Eye Group	Vestal	New York

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population)	Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.	Baseline (Visit 1) and 1-week follow up (Visit 2)
Primary	Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population)	Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.	Baseline (Visit 1) and 1-week follow up (Visit 2)
Secondary	The Number of Eyes With Clinically Significant Slit Lamp Findings	Slit lamp findings were assessed using a biomicroscope for each subject eye at all scheduled and unscheduled visits. Clinical significant slit lamp findings are defined as Grade 3 or Grade 4. (Grade 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate and Grade 4= Severe). The data was dichotomized as 1=Grade 3 or Grade 4 and 0, otherwise. The number of eyes with clinically significant slit lamp findings for each lens type was reported.	Up to 1-Week Follow-up
Secondary	The Number of Eyes With Unacceptable Lens Fitting	Lens fit was assessed for each subject and eye using a biomicroscope. Unacceptable lens fit was assessed at all scheduled and unscheduled visits. A subject was deemed to have an unacceptable lens fitting if they met any of the following criteria: (1) Limbal exposure at primary gaze with extreme eye movement, (2) edge lift, (3) excessive movement in primary up gaze, (4) insufficient movement in all three of the following conditions: primary gaze, up gaze and push up test. The number of eyes with unacceptable lens fitting was reported for each lens type.	Up to 1-Week Follow-up